ABSTRACT

The current advancement in pharmacoepidemiology does not only analyze the use and effect of drugs in terms of its efficacy and safety, but also through the economic perspective. Antibiotic is one of the drugs that are widely used as a consequence of the abundance of infectious diseases, including pneumonia. This study aimed to analyze the cost-effectiveness between levofloxacin and ceftriaxone-azithromycin antibiotics as the most used drugs among pneumonia patients in Persahabatan Hospital in 2017. This study was an observational analytic study using a cross-sectional method in 19 patients. A total sampling method was used to collect the samples while parametric unpaired T-test test was used to analyze the data. There were not any differences in total cost (p=0.338) and length of stay (p=0.121) between patients administered with levofloxacin and ceftriaxone-azithromycin. Pharmacoeconomically, levofloxacin antibiotics are the most cost-effective according to the interpretation of the cost-effectiveness table. Levofloxacin remains as the best choice because its use is more practical than ceftriaxone-azithromycin drugs.

Keywords: azithromycin; ceftriaxone; community-acquired pneumonia; levofloxacin; pharmacoeconomic